Single brain metastasis

被引:64
作者
David Schiff
机构
[1] University of Pittsburgh,Departments of Neurologic Surgery, Neurology, and Medicine
关键词
Brain Metastasis; Radiat Oncol Biol Phys; Karnofsky Performance Status; Radiation Therapy Oncology Group; Recursive Partition Analysis;
D O I
10.1007/s11940-001-0027-4
中图分类号
学科分类号
摘要
The management of single brain metastases has evolved substantially over the last decade. The advent of triple-dose contrast-enhanced MRI scans has improved the radiologists’ capacity to resolve small tumors, and, thereby, has resulted in a declining percentage of brain metastases classified as single. Only 25% to 30% of brain metastases are single; single brain metastases in the absence of systemic metastases are termed solitary. Randomized trials suggest that patients not in imminent danger of herniation are best managed initially with dexamethasone 2 to 4 mg administered orally twice daily. The routine use of prophylactic anticonvulsants is discouraged. Patients with refractory progressive systemic tumor likely to prove fatal within 3 to 6 months should receive fractionated whole brain radiotherapy. Patients with highly radiosensitive primary tumors such as small cell lung cancer, lymphoma, and germinoma should also receive whole brain radiotherapy. Patients with inactive or controllable systemic cancer and good performance status benefit from the addition of local strategies like surgery or radiosurgery to whole brain radiotherapy. Although surgery and radiosurgery have not been compared in a randomized controlled trial, data suggest that results are similar. Consequently, for most metastases that fall within the size constraints of radiosurgery (3.5 cm or smaller in diameter), radiosurgery is preferred for its relatively noninvasive nature. Patients with larger or cystic tumors, with obstructive hydrocephalus, or neurologic instability despite corticosteroids are best treated with craniotomy. Fractionated whole brain radiation following surgical or radiosurgical management of single brain metastasis appears to decrease the risk of recurrent brain metastasis, although it has not been shown to improve survival. We recommend its use in most patients, although patients with tumors likely to be highly resistant to fractionated radiotherapy or at high risk of radiation neurotoxicity may reasonably defer its use.
引用
收藏
页码:89 / 99
页数:10
相关论文
共 125 条
  • [1] Schellinger PD(1999)Diagnostic accuracy of MRI compared to CCT in patients with brain metastases J Neurooncol 44 275-281
  • [2] Meinck HM(1994)Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases AJNR Am J Neuroradiol 15 1037-1051
  • [3] Thron A(1995)The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis AJNR Am J Neuroradiol 16 373-380
  • [4] Yuh WT(1998)Comparison of single- and triple-dose contrast material in the MR screening of brain metastases AJNR Am J Neuroradiol 19 821-828
  • [5] Fisher DJ(1994)Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases AJNR Am J Neuroradiol 15 1053-1061
  • [6] Runge VM(1999)Magnetic resonance imaging of brain metastases: magnetisation transfer or triple dose gadolinium? Ann Acad Med Singapore 28 529-533
  • [7] Yuh WT(1998)Contrastenhanced magnetisation transfer MRI in metastatic lesions of the brain Neuroradiol 40 783-787
  • [8] Tali ET(1989)Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916 Int J Radiat Oncol Biol Phys 16 669-673
  • [9] Nguyen HD(1999)Identification of prognostic factors in patients with brain metastases: a review of 1292 patients Int J Radiat Oncol Biol Phys 43 795-803
  • [10] Sze G(1998)Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases Int J Radiat Oncol Biol Phys 42 155-159